NCT04615221 Immunological Mechanisms of Rejection in Uterine Transplantation
| NCT ID | NCT04615221 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hopital Foch |
| Condition | Transplant Rejection |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2020-09-21 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2020-09-21 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to understand the mechanisms of rejection in uterine transplantation and to search for non-invasive markers of rejection. The biological samples necessary for our research have been or will be collected during procedures (biopsies, smears, vaginal swab, blood tests) carried out as part of the scheduled follow-up of patients. These will be samples whose collection is minimally or not invasive
Eligibility Criteria
Inclusion Criteria: * Patient going to or having received a uterine transplant OR Patient going to or having donated a uterus for a recipient included in the study OR Premenopausal woman to undergo gynecological surgery under general anesthesia: for 4 of them it was a hysterectomy and they must be under 45 years old, the other 6 must be under 38 years old. Exclusion Criteria (For witness): * Pregnancy in progress * Current infection * Cervical dysplasia * History of transplant or transfusion * Cancer or history of cancer * Menopause * Patient aged 38 or over for the 6 controls without hysterectomy, patient aged 45 or over for the 4 patients with hysterectomy. * Endometriosis
Contact & Investigator
Jean-Marc Ayoubi, MD, PhD
PRINCIPAL INVESTIGATOR
Hopital Foch
Frequently Asked Questions
Who can join the NCT04615221 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Transplant Rejection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04615221 currently recruiting?
Yes, NCT04615221 is actively recruiting participants. Contact the research team at m.carbonnel@hopital-foch.com for enrollment information.
Where is the NCT04615221 trial being conducted?
This trial is being conducted at Suresnes, France.
Who is sponsoring the NCT04615221 clinical trial?
NCT04615221 is sponsored by Hopital Foch. The principal investigator is Jean-Marc Ayoubi, MD, PhD at Hopital Foch. The trial plans to enroll 30 participants.